Marshall Wace’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Marshall Wace’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-43,678	Closed	-$1.53M	–	3137
2024 Q1	$1.53M	Buy	+43,678	New	+$1.59M	﹤0.01%	1480
2023 Q4	–	Sell	-103,243	Closed	-$1.89M	–	2789
2023 Q3	$1.89M	Buy	103,243 +91,550	+783%	+$1.92M	﹤0.01%	1248
2023 Q2	$304K	Buy	+11,693	New	+$273K	﹤0.01%	2138
2023 Q1	–	Sell	-31,480	Closed	-$776K	–	3575
2022 Q4	$776K	Buy	+31,480	New	+$925K	﹤0.01%	2195
2021 Q3	–	Sell	-12,078	Closed	-$332K	–	3700
2021 Q2	$332K	Buy	+12,078	New	+$252K	﹤0.01%	2293

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Marshall Wace's INBX Position: Q2 2024 in Review

Marshall Wace sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 43,678 shares — an estimated $1.53M sold.

Marshall Wace first reported a position in INBX in Q2 2021 and held it in 5 quarters. The position peaked at $1.89M in Q3 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Marshall Wace reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Marshall Wace sold 43,678 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $1.53M.
Marshall Wace first reported a position in Inhibrx, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Marshall Wace's Inhibrx, Inc. Common Stock position peaked at $1.89M in Q3 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.